AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014
11/12/2013 1:36:49 PM
PARIS, Nov. 12, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), following the press release from November 11th that announced the phase 3 study's success in the futility analysis, further specifies important points concerning availability of phase 3 data, number of patients treatable and sustainability of response generated by masitinib observed in phase 2.
Help employers find you! Check out all the jobs and post your resume.